FLT3 and acute myeloid leukemia: Other first and second generation of inhibitors for FLT3 such as Sorafenib (NCT01398501) (31) and Quizartinib (NCT02668653) (in newly diagnosed AML) (8), have currently reached late stages of clinical testing.